Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK

INTRODUCTION: Darunavir (DRV) is a preferred agent in treatment guidelines for ART-naïve and experienced patients [1]. It is considered to have a high genetic barrier to resistance and 11 resistance-associated mutations (RAMs) are recognized by IAS-USA [2]. These have largely been identified by anal...

Descripción completa

Detalles Bibliográficos
Autores principales: El Bouzidi, Kate, White, Ellen, Mbisa, Jean L, Phillips, Andrew, Mackie, Nicola, Pozniak, Anton, Dunn, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P207
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225433/
https://www.ncbi.nlm.nih.gov/pubmed/25397484
http://dx.doi.org/10.7448/IAS.17.4.19739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225433/
https://www.ncbi.nlm.nih.gov/pubmed/25397484
http://dx.doi.org/10.7448/IAS.17.4.19739

Ejemplares similares